May Hill Capital’s Taysha Gene Therapies TSHA Stock Holding History

May Hill Capital’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-16,051	Closed	-$37.1K	–	215
2025 Q2	$37.1K	Buy	+16,051	New	+$34.9K	0.01%	198

Other funds holding TSHA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

May Hill Capital's TSHA Position: Q3 2025 in Review

May Hill Capital sold out of Taysha Gene Therapies (TSHA) in Q3 2025, closing a stake of 16,051 shares — an estimated $37.1K sold.

May Hill Capital first reported a position in TSHA in Q2 2025 and held it in 1 quarter. The position peaked at $37.1K in Q2 2025. 155 funds tracked by Wall St. Rank hold TSHA as of Q3 2025.

May Hill Capital reported no remaining Taysha Gene Therapies position as of Q3 2025 after selling out during the quarter.
May Hill Capital sold 16,051 Taysha Gene Therapies shares in Q3 2025, an estimated $37.1K.
May Hill Capital first reported a position in Taysha Gene Therapies in Q2 2025 and held it in 1 quarter.
May Hill Capital's Taysha Gene Therapies position peaked at $37.1K in Q2 2025.
155 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2025.

Based on May Hill Capital's 13F filing for Q3 2025, filed 7 Nov 2025.